Apparently Southern Cross equity's have put in their weekly report that they are talking more about a valuation of $1.00 (previously 72c). I think it depends on sucessfully moving to Phase 2 trials but considering they have had sucess in 1a and 1b this should be ok.
See previous posts about bioshares recommending as a strong buy last Friday at 64c
Apparently Southern Cross equity's have put in their weekly...
Add to My Watchlist
What is My Watchlist?